A team of US scientists has initiated a clinical trial to evaluate the effectiveness of sipavibart, a long-acting monoclonal antibody designed to combat Long Covid, a condition affecting at least 65 million people worldwide.
The study, led by researchers from Nova Southeastern University (NSU) and the Schmidt Initiative for Long Covid (SILC), aims to determine whether sipavibart, previously approved for Covid-19 prevention in Japan and the EU, can help alleviate Long Covid symptoms.
The multi-year research, reviewed and cleared by the FDA, has enrolled 100 patients to assess the antibody’s safety and efficacy. Experts believe that finding an effective treatment could be life-changing for those suffering from the more than 200 symptoms associated with Long Covid.
Dr. Nancy Klimas, director of the Institute for Neuro-Immune Medicine at NSU, emphasized the complexity of Long Covid, while Dr. John Redd, CEO of SILC, highlighted the debilitating health impacts of the condition.
This trial is one of three Long Covid treatment studies expected to begin in 2025, marking a significant step toward advancing knowledge and improving patient outcomes.